BGI SENTIS™ Lung Cancer Panel
Introduction
BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported.
BGI’s lung cancer panel covers 11 genes with direct therapeutic implications for 20 targeted drugs, including those recommended in the latest NCCN guidelines. The panel detects all classes of genomic alterations including SNV, CNV, InDels and Fusion using routine FFPE samples, tumor tissue, DNA or peripheral blood.
Why Choose BGI SENTIS™ Lung Cancer Panel?
- Fast
- Accurate
- Affordable
Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.
Workflow
Ordering the BGI SENTIS™ Lung Cancer Panel is easy.
